Clinical course and outcomes in patients with Mooren ulcer who had cataract surgery
- 1 August 2017
- journal article
- Published by Ovid Technologies (Wolters Kluwer Health) in Journal of Cataract & Refractive Surgery
- Vol. 43 (8), 1044-1049
- https://doi.org/10.1016/j.jcrs.2017.05.034
Abstract
Purpose To report outcomes of cataract surgery in patients with Mooren ulcer. Setting L.V. Prasad Eye Institute, Hyderabad, India. Design Retrospective case series. Methods The medical records of patients with Mooren ulcer who had cataract surgery between 2000 and 2015 were assessed. The main outcome measures were the role of preoperative immunosuppression and disease inactivity, cataract surgery safety, visual outcomes, and postoperative ulcer recurrence. Results Of 22 patients (26 eyes), the mean corneal ulceration was 6.8 clock hours ± 2.9 (SD). Corticosteroids were the most commonly used (84.6% of the 26 eyes) preoperative immunosuppression agents and 38.5% of the 26 eyes were under maintenance immunosuppression. The median disease inactivity before surgery was 7 months. Cataract surgery was extracapsular in 10 patients, small incision in 3 patients, and phacoemulsification in 13 patients. Twenty-two eyes had scleral incisions. The median follow-up was 6 months (interquartile range, 10 months). The median corrected distance visual acuity (CDVA) improved from 1.48 logarithm of minimum angle of resolution (logMAR) before surgery to 0.30 and 0.35 logMAR at 1 month and at the last follow-up after surgery, respectively (P ≤ .0001). Mooren ulcer recurred in 5 eyes between 3 months and 7 years after surgery. No disease activity was seen in the immediate postoperative period. No significant risk factors for disease recurrence were noted. Conclusions With adequate immunosuppression, cataract surgery in eyes with Mooren ulcer was safe and CDVA improved significantly with no disease reactivation immediately after surgery. No proven role of maintenance immunosuppression was observed. The type of cataract surgery had no influence on ulcer reactivation. Patients with a disease-free interval of 6 months or more before surgery and those who had scleral incisions had favorable outcomes.Keywords
This publication has 10 references indexed in Scilit:
- Immunosuppression for Mooren's ulcer: evaluation of the stepladder approach—topical, oral and intravenous immunosuppressive agentsBritish Journal of Ophthalmology, 2013
- Hookworm Infestation as a Risk Factor for Mooren’s Ulcer in South IndiaOphthalmology, 2007
- Mooren UlcerCornea, 2006
- Cataract surgery in patients with advanced Mooren's ulcer.Japanese Journal of Ophthalmology, 2001
- Mooren ulcer in South India: serology and clinical risk factorsAmerican Journal of Ophthalmology, 1999
- Cytokine-Induced Calgranulin C Expression in KeratocytesClinical Immunology, 1999
- Phacoemulsification and Intraocular Lens Implantation in a Patient With Mooren's UlcerOphthalmic Surgery, Lasers and Imaging Retina, 1997
- Therapy of Mooren's UlcerAmerican Journal of Ophthalmology, 1984
- Presence of Circulating Immune Complexes in Patients With Peripheral Corneal DiseaseAmerican Journal of Ophthalmology, 1983
- Autoimmune Phenomenon in Mooren's UlcerAmerican Journal of Ophthalmology, 1976